In a recent extension study, researchers found reslizumab was safe, efficacious and improved Asthma Quality of Life scores for up to 2 years after beginning treatment, according to data recently presented at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting.
“The significant improvement in [Asthma Quality of Life (AQLQ)] scores observed with reslizumab during placebo-controlled trials was sustained, without diminution, with continued open-label reslizumab 3.0 mg/kg once every 4 weeks for up to 2 years,” Joshua S. Jacobs, MD, from Walnut Creek, Calif., and colleagues wrote in their study abstract. “Reslizumab meaningfully improved AQLQ scores in reslizumab-naive patients during the treatment period, and was well tolerated in this long-term extension study.”
The 1,052 patients in this extension study (aged between 12 years and 75 years) were previously enrolled in three placebo-controlled phase 3 trials in which they had poor asthma control and elevated blood eosinophils (≥400/μL), according to the abstract. In these trials, patients received reslizumab between 16 weeks and 52 weeks and achieved reduced asthma exacerbations and improved lung function.
In the extension study, patients were assigned reslizumab 3.0 mg/kg once every 4 weeks for up to 2 years, according to the abstract. The patients were divided into reslizumab-naive (n = 480) and reslizumab-experienced (n = 571) groups. The researchers measured long-term safety and efficacy as well as AQLQ scores.
Although the reslizumab-experienced patients sustained baseline AQLQ scores (5.94) during the study period, there was an improvement of 0.31 at 96 weeks in treatment, according to the abstract. There was an improvement of 0.395 in AQLQ scores at 24 weeks in treatment, and a (≥ 0.5 units) improvement at 96 weeks in treatment. Jacobs and colleagues noted there were also improvements in emotional function of 0.843 and symptoms of 0.596 for individual AQLQ domains.
About 10% of the patients had nasopharyngitis and asthma and upper respiratory tract infections; however, the researchers noted there were similar adverse event levels between the reslizumab-naive and reslizumab-experienced groups. – by Jeff Craven
For more information:
Jacobs J, et al. Abstract P62. Presented at: American College of Allergy, Asthma and Immunology
Annual Scientific Meeting; Nov. 5-9; San Antonio.
Disclosure: Healio.com was unable to confirm relevant financial disclosures at press time.